EW Healthcare discloses 17.23% stake in TELA Bio

EW Healthcare Partners funds report a 17.23% beneficial stake in TELA Bio, Inc. common stock, totaling 7,714,709 shares.

Rhea-AI Filing Summary

EW Healthcare Partners funds report a 17.23% beneficial stake in TELA Bio, Inc. common stock, totaling 7,714,709 shares. The stake is held through EW Healthcare Partners Fund 2, L.P., EW Healthcare Partners Fund 2-A, L.P., their general partner entities, and related structures.

The filing states that on June 9, 2026, an operating partner affiliated with the reporting persons was appointed to TELA Bio's Board of Directors. Ownership percentages are based on 44,766,146 shares outstanding as of May 5, 2026, as reported by TELA Bio in a recent Form 10-Q.

Insights

Equity ownership & governance analyst

Large healthcare investor holds 17.23% of TELA Bio and gains board representation.

The filing shows EW Healthcare Partners-affiliated funds collectively beneficially own 7,714,709 TELA Bio common shares, representing 17.23% of the company’s outstanding stock, based on 44,766,146 shares as of May 5, 2026. This is a significant, but not majority, position.

The report notes that an operating partner affiliated with these funds joined TELA Bio’s Board on June 9, 2026, providing direct governance influence. The filing also states the funds currently have no additional plans or proposals relating to major corporate actions, beyond this board appointment.

The impact of this stake and board seat will depend on future disclosures about strategy and any subsequent changes to EW Healthcare’s ownership level or stated intentions, which would typically appear in later ownership or company filings.

Key Figures

EWHP2 beneficial ownership: 3,031,617 shares EWHP2-A beneficial ownership: 4,683,092 shares Aggregate beneficial ownership: 7,714,709 shares +5 more

8 metrics

EWHP2 beneficial ownership 3,031,617 shares EW Healthcare Partners Fund 2, L.P. sole voting and dispositive power

EWHP2-A beneficial ownership 4,683,092 shares EW Healthcare Partners Fund 2-A, L.P. sole voting and dispositive power

Aggregate beneficial ownership 7,714,709 shares Total shares reported beneficially owned by reporting persons

Ownership percentage 17.23% Percent of TELA Bio common stock represented by 7,714,709 shares

Shares outstanding baseline 44,766,146 shares TELA Bio common shares outstanding as of May 5, 2026

EWHP2 percent of class 6.77% EW Healthcare Partners Fund 2, L.P. portion of TELA Bio common stock

EWHP2-A percent of class 10.46% EW Healthcare Partners Fund 2-A, L.P. portion of TELA Bio common stock

Event date June 9, 2026 Date affiliated operating partner joined TELA Bio’s Board of Directors

Key Terms

beneficially owned, Schedule 13D, growth capital investments, sole voting power, +2 more

6 terms

beneficially owned financial

"Aggregate amount beneficially owned by each reporting person 7,714,709.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Schedule 13D regulatory

"This is being filed jointly by EW Healthcare Partners Fund 2, L.P...."

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

growth capital investments financial

"The principal business of each of EWHP2 and EWHP2-A is growth capital investments."

sole voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: 7 | Sole Voting Power 7,714,709.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"9 | Sole Dispositive Power 7,714,709.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Joint Filing Agreement regulatory

"Exhibit 1: Joint Filing Agreement, dated June 9, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of TELA Bio (TELA) does EW Healthcare Partners report owning?

EW Healthcare Partners-affiliated funds report beneficially owning 17.23% of TELA Bio’s common stock, representing 7,714,709 shares. This percentage is calculated using 44,766,146 shares outstanding as of May 5, 2026, as disclosed in TELA Bio’s Form 10-Q.

How many TELA Bio (TELA) shares are beneficially owned by EW Healthcare funds?

The filing states that EW Healthcare Partners-related entities beneficially own 7,714,709 TELA Bio common shares. This aggregate figure reflects holdings attributed to EW Healthcare Partners Fund 2, L.P., EW Healthcare Partners Fund 2-A, L.P., and their general partner entities under shared management control.

Which EW Healthcare entities are reporting ownership in TELA Bio (TELA)?

The reporting persons are EW Healthcare Partners Fund 2, L.P., EW Healthcare Partners Fund 2-A, L.P., EW Healthcare Partners Fund 2-GP, L.P., and EW Healthcare Partners Fund 2-UGP, LLC. All are Delaware entities with a principal office in The Woodlands, Texas.

On what share count is EW Healthcare’s TELA Bio (TELA) ownership percentage based?

The reported ownership percentages are based on 44,766,146 TELA Bio common shares outstanding as of May 5, 2026. This outstanding share figure comes from TELA Bio’s Form 10-Q filed with the SEC on May 13, 2026, and is used for the 13D calculations.

Did EW Healthcare gain board representation at TELA Bio (TELA)?

Yes. The filing notes that on June 9, 2026, an operating partner affiliated with the reporting persons was appointed to TELA Bio’s Board of Directors. This appointment is cited as the key purpose-related event associated with the ownership disclosure.

Does EW Healthcare state any plans for major corporate actions at TELA Bio (TELA)?

The reporting persons state they have no present plan or proposal relating to the types of major corporate actions listed in Item 4, other than the board appointment disclosed. They also note there are no additional contracts or arrangements regarding TELA Bio securities beyond this context.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 06:29 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

TELA Bio, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

872381108

(CUSIP Number)

R. Scott Barry
21 Waterway Avenue, Suite 150,
The Woodlands, TX, 77380
281-364-1555

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/09/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 872381108

1

Name of reporting person

EW HEALTHCARE PARTNERS FUND 2, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,031,617.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,031,617.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,031,617.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.77 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 872381108

1

Name of reporting person

EW HEALTHCARE PARTNERS FUND 2-A, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 4,683,092.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 4,683,092.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

4,683,092.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.46 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 872381108

1

Name of reporting person

EW Healthcare Partners Fund 2-GP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,714,709.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 7,714,709.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

7,714,709.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

17.23 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 872381108

1

Name of reporting person

EW Healthcare Partners Fund 2-UGP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,714,709.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 7,714,709.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

7,714,709.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

17.23 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: TELA Bio, Inc.
(c)	Address of Issuer's Principal Executive Offices: 1 Great Valley Parkway, Suite 24, Malvern, PENNSYLVANIA , 19355.
Item 2.	Identity and Background
(a)	This Schedule 13D is being filed jointly by EW Healthcare Partners Fund 2, L.P., a Delaware limited partnership ("EWHP2"), EW Healthcare Partners Fund 2-A, L.P., a Delaware limited partnership ("EWHP2-A"), EW Healthcare Partners Fund 2-GP, L.P., a Delaware limited partnership ("EWHP2 GP"), and EW Healthcare Partners Fund 2-UGP, LLC, a Delaware limited liability company ("EWHP2 General Partner" and collectively with EWHP2, EWHP2-A and EWHP2 GP, the "Reporting Persons"), and relates to shares of common stock, par value $0.001 per share ("Common Stock"), of TELA Bio, Inc. (the "Issuer"). The managers of the Reporting Persons are R. Scott Barry, an individual, Martin P. Sutter, an individual, Ronald Eastman, an individual and Petri Vainio, an individual (collectively, the "Managers"). The Managers may exercise voting and investment control over the shares of Common Stock only by majority action of the Managers. Each individual Manager disclaims beneficial ownership over the shares of Common Stock except to the extent of his respective pecuniary interest therein.
(b)	The address of the principal business office of each of the Reporting Persons is 21 Waterway Avenue, Suite 150, The Woodlands, Texas 77380.
(c)	The principal business of each of EWHP2 and EWHP2-A is growth capital investments. The principal business of EWHP2 GP is to act as the general partner of EWHP2 and EWHP2-A. The principal business of EWHP2 General Partner is to act as the general partner of EWHP2 GP.
(d)	None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	None of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Each of EWHP2, EWHP2-A, and EWHP2 GP is a Delaware limited partnership. EWHP2 General Partner is a Delaware limited liability company.
Item 3.	Source and Amount of Funds or Other Consideration
	The funds used to purchase the securities reported herein came from the working capital of EWHP and EWHP-A.
Item 4.	Purpose of Transaction
	The disclosure set forth in Item 6 below is hereby incorporated by reference in this Item 4. This Schedule 13D reports that, on June 9, 2026, an operating partner affiliated with the Reporting Persons was appointed to the Board of Directors of the Issuer. Except as described above, none of the Reporting Persons has any present plan or proposal which relates to, or could result in, any of the events referred to in paragraphs (a) through (j), inclusive, of Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	The information set forth in Rows 7 through 13 of the cover page hereto for each Reporting Person is incorporated herein by reference for each such Reporting Person. The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 44,766,146 shares of Common Stock outstanding as of May 5, 2026, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 13, 2026.
(b)	Refer to Item 5.(a) above.
(c)	None.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The disclosure set forth in Item 4 above is hereby incorporated by reference in this Item 6. Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between such persons and any other person with respect to any securities of the Issuer, including but not limited to the transfer or voting of any securities of the Issuer, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1: Joint Filing Agreement, dated June 9, 2026

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EW HEALTHCARE PARTNERS FUND 2, L.P.

Signature:	/s/ R. Scott Barry
Name/Title:	EW Healthcare Partners Fund 2-GP, L.P., its General Partner, EW Healthcare Partners Fund 2-UGP, LLC, its General Partner, R. Scott Barry, Manager
Date:	06/09/2026

EW HEALTHCARE PARTNERS FUND 2-A, L.P.

Signature:	/s/ R. Scott Barry
Name/Title:	EW Healthcare Partners Fund 2-GP, L.P., its General Partner, EW Healthcare Partners Fund 2-UGP, LLC, its General Partner, R. Scott Barry, Manager
Date:	06/09/2026

EW Healthcare Partners Fund 2-GP, L.P.

Signature:	/s/ R. Scott Barry
Name/Title:	EW Healthcare Partners Fund 2-UGP, LLC, its General Partner, R. Scott Barry, Manager
Date:	06/09/2026

EW Healthcare Partners Fund 2-UGP, LLC

Signature:	/s/ R. Scott Barry
Name/Title:	R. Scott Barry, Manager
Date:	06/09/2026